A Prospective Study of Surgical Treatment Strategies for Chordoma

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT05707767

Enrollment

100

Registered

2023-02-01

Start date

2023-02-01

Completion date

2024-09-30

Last updated

2023-07-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chordoma of Spine, Surgery

Keywords

chordoma

Brief summary

Chordoma is a rare but locally invasive cancer that arises from the embryonic notochord. Total resection is challenging in mobile spine because of the complex anatomy and bone invasion.

Interventions

PROCEDUREResection surgery

Patients undergo resection surgery in our hospital.

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 70 Years

Healthy volunteers

Inclusion criteria

* Between the ages of 18 and 70 ys, * With a diagnosis of chordoma confirmed by pathology, * Undergone surgical treatment in our hospital, * Available for clinical follow-up and agree to long-term clinical follow-up and sign informed consent.

Exclusion criteria

* Suffer from other tumors, * Suffer from cardiovascular disease, cerebrovascular disease, or immune system disease.

Design outcomes

Primary

Measure	Time frame	Description
Excision Extension	1 week after surgery.	Clinical and radiographic assessments of excision extension of tumor.

Secondary

Measure	Time frame	Description
OS (Overall Survival)	2 years	Overall Survival of patient underwent surgery.
PFS (Progression-Free Survival)	2 years	Progression-Free Survival of patient underwent surgery.
DFS (Disease Free Survival)	2 years	Disease Free Survival of patient underwent surgery.
ORR (Objective Response Rate)	2 years	Objective Response Rate of patient underwent surgery.

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026